Trigeminal Neuralgia Clinical Trials 2024

What are the top hospitals conducting trigeminal neuralgia research?

Trigeminal neuralgia, a debilitating condition characterized by severe facial pain, is being tackled head-on by some of the top hospitals in North America. In Minneapolis, the University of Minnesota leads the charge with one active clinical trial focused on finding effective treatments for this excruciating ailment. Toronto Western Hospital in Canada's bustling city of Toronto is also making strides, currently conducting its own trigeminal neuralgia trial as part of the renowned University Health Network. Across the continent in San Francisco, UCSF Medical Center joins the fight against trigeminal neuralgia with an ongoing clinical trial aimed at improving patients' quality of life. Meanwhile, in Southern California's sunny La Jolla area, Kaizen Brain Center has taken up this challenge and initiated their first-ever trigeminal neuralgia trial to explore innovative approaches to managing this condition. Lastly but no less significant is Florida's prestigious University of South Florida located in Tampa where they are actively engaged in investigating new and improved strategies for treating trigeminal neuralgia alongside their fellow institutions.

These dedicated medical centers recognize that trigeminal neuralgia can have a tremendous impact on patients' lives and relentlessly work towards delivering relief from its relentless agony. By pooling resources and expertise through these cutting-edge trials conducted simultaneously across different locations throughout North America — each recording their first ever investigation into trigeminal neuralgia during 2022 — these hospitals offer hope to those suffering from this challenging neurological disorder that affects countless individuals worldwide.

Which are the best cities for trigeminal neuralgia clinical trials?

When it comes to trigeminal neuralgia clinical trials, several cities are at the forefront of research and development. Boston, Massachusetts has 2 active trials focusing on treatments like Basimglurant and Botulinum toxin type A injection arm. Minneapolis, Minnesota has 1 ongoing trial exploring various approaches for TGN patients. Toronto, Ontario is also home to a single active trial studying Paresthesia-Free Stimulation among other treatment options. San Francisco, California and La Jolla, California each have one active trial investigating High Frequency rTMS and Basimglurant respectively. These cities offer individuals with trigeminal neuralgia access to potential breakthroughs through cutting-edge clinical trials conducted by leading researchers in the field.

Which are the top treatments for trigeminal neuralgia being explored in clinical trials?

Trigeminal neuralgia patients can find hope in the ongoing exploration of various treatments through clinical trials. High Frequency rTMS, a cutting-edge therapy, is currently being tested in one active trial dedicated to combating this condition. Another promising option is basimglurant, also under investigation in one active trigeminal neuralgia trial. And not to be overlooked is the ExAblate Transcranial treatment, which made its debut in 2021 and is now being studied extensively with one active trial focusing on its potential benefits for trigeminal neuralgia patients. These trials mark significant progress towards finding effective solutions for those suffering from this debilitating condition.

What are the most recent clinical trials for trigeminal neuralgia?

Exciting developments are underway in the field of trigeminal neuralgia, with recent clinical trials offering promising new avenues for treatment. One such trial is investigating paresthesia-free stimulation as a potential solution. This innovative approach aims to provide relief from trigeminal neuralgia without the uncomfortable tingling sensations commonly associated with traditional stimulation methods. Additionally, basimglurant has shown potential in Phase 2 and Phase 3 trials as an effective treatment option for this debilitating condition. Guanfacine, another drug under investigation, has displayed encouraging results during its Phase 2 trial phase. Lastly, a Phase 4 trial focusing on botulinum toxin type A injections explores their effectiveness in managing trigeminal neuralgia symptoms. With these exciting advancements taking place, there is renewed hope for individuals living with this challenging condition.

What trigeminal neuralgia clinical trials were recently completed?

In July 2020, Duke University concluded a clinical trial investigating the effectiveness of Galcanezumab in managing trigeminal neuralgia. This recent completion marks an important milestone in the ongoing pursuit of improved treatments for this debilitating condition. The study outcomes will contribute valuable insights into the potential benefits and efficacy of Galcanezumab as a therapeutic option for individuals affected by trigeminal neuralgia.